Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.46 USD | -1.67% | +5.38% | +7.85% |
Financials (USD)
Sales 2024 * | 401M | Sales 2025 * | 486M | Capitalization | 1.33B |
---|---|---|---|---|---|
Net income 2024 * | -128M | Net income 2025 * | -74M | EV / Sales 2024 * | 3.91 x |
Net Debt 2024 * | 234M | Net Debt 2025 * | 259M | EV / Sales 2025 * | 3.27 x |
P/E ratio 2024 * |
-10.6
x | P/E ratio 2025 * |
-16.1
x | Employees | 536 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.01% |
Latest transcript on BioCryst Pharmaceuticals, Inc.
1 day | -1.67% | ||
1 week | +5.38% | ||
1 month | +41.36% | ||
3 months | +14.95% | ||
6 months | +5.04% | ||
Current year | +7.85% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 20-04-01 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 20-02-26 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Director/Board Member | 60 | 21-07-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.23% | 0 M€ | 0.00% | - | |
0.20% | 0 M€ | 0.00% | - | |
0.18% | 1,085 M€ | +9.05% | - | |
0.13% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 6.46 | -1.67% | 3,831,914 |
24-05-30 | 6.57 | +6.83% | 4,174,247 |
24-05-29 | 6.15 | -0.65% | 3,061,873 |
24-05-28 | 6.19 | +0.98% | 3,690,555 |
24-05-24 | 6.13 | -3.16% | 2,147,600 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.85% | 1.33B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- BCRX Stock